英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
realta查看　realta　在百度字典中的解释百度英翻中〔查看〕
realta查看　realta　在Google字典中的解释Google英翻中〔查看〕
realta查看　realta　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • About ReAlta | Advancing HIE Treatment
    ReAlta is developing pegtarazimod, a Phase 2 therapy targeting neonatal HIE to protect the newborn brain and improve outcomes
  • ReAlta Life Sciences Announces New Clinical Data for RLS-0071 . . .
    Data confirm elevated inflammatory biomarkers in newborns with Hypoxic Ischemic Encephalopathy (HIE) and demonstrate a predictable pharmacokinetic profile for RLS-0071 (pegtarazimod) NORFOLK, Va –ReAlta Life Sciences, Inc (“ReAlta” or the “Company”), a clinical-stage biopharmaceutical company dedicated to saving lives by rebalancing the inflammatory response to address rare and
  • ReAlta Life Sciences Announces First Patient Dosed in Phase 2 Study . . .
    Norfolk, VA –September 23, 2024 – ReAlta Life Sciences, Inc (“ReAlta” or the “Company”), a clinical-stage biopharmaceutical company dedicated to saving lives by rebalancing the inflammatory response to address rare and acute inflammatory diseases, today announced that the first patient has been dosed in its Phase 2 study of RLS
  • Press Releases - Realta Life Sciences
    Press Releases Stay up to date on ReAlta’s news, scientific progress, clinical milestones, and mission to address severe inflammatory disease Years Years 2018 2019
  • ReAlta Granted FDA Orphan Drug Designation and Fast Track Designation . . .
    This designation provides ReAlta with certain benefits, including seven years of market exclusivity upon regulatory approval, exemption from FDA application fees, and tax credits for qualified clinical trials In addition to the Orphan Drug Designation, RLS-0071 has also received FDA Fast Track Designation for the treatment of aGvHD
  • Pipeline | Pegtarazimod for HIE - Realta Life Sciences
    Explore ReAlta’s clinical pipeline, led by pegtarazimod, a Phase 2 therapy advancing disease modification in neonatal HIE
  • Our Science | Targeting Neonatal HIE - Realta Life Sciences
    Learn how ReAlta targets upstream inflammatory drivers of neonatal HIE with pegtarazimod to protect the newborn brain
  • ReAlta Life Sciences Receives FDA Clearance for Phase 2 Trial of RLS . . .
    Third clinical indication under evaluation for RLS-0071, demonstrating the broad potential of ReAlta’s lead dual-action complement and innate inflammatory inhibitor Norfolk, VA – October 24, 2023 – ReAlta Life Sciences, Inc (“ReAlta” or the “Company”), a mid-stage clinical biotech company focused on harnessing the power of the immune system to address life-threatening diseases
  • ReAlta Life Sciences Announces Dosing of First Patient in Phase 2 Trial . . .
    Norfolk, VA – February 21, 2024 – ReAlta Life Sciences, Inc (“ReAlta” or the “Company”), a mid-stage clinical biotech company dedicated to saving lives by rebalancing the inflammatory response to address life-threatening diseases, today announced enrollment of the first patient in a Phase 2 clinical trial evaluating the safety and efficacy of RLS-0071, an investigational […]





中文字典-英文字典  2005-2009